Antibody Production
Antibody discovery and development is starting to bear fruit with a number of therapeutic antibodies having been approved for treatment. As patents concerning technologies and techniques begin to expire, there is a need to ensure advancement is made, with application of new processes implemented, to discover novel antibody formats for production at a large scale.
STAB VIDA offers antibody discovery and development, using leading technologies and techniques with a clinical perspective. Choose our service for:
- Cutting-edge advancements with leading techniques in generation of novel antibody formats.
- Use of recent developments in the engineering of antibody-drug conjugates to understand approaches towards linker innovation and stability.
- Follow an effective strategy to see advancement through clinical stages.
- Antibodies raised towards the same target using combinatorial technology.
- Undergo developments regarding glycoengineering and how to achieve increased potency.
Our monoclonal antibodies provide single epitope specificity and limitless amounts of identical antibody:
Antigen Selection
Send us your proteins, peptides, haptens, or chemical compounds, to be used to generate antibodies. Synthetic short peptides will generate protein-reactive antibodies. Most peptides will elicit a good response. The advantage of anti-peptide antibodies is that they can be prepared immediately after determining the amino acid sequence of a protein and the particular regions of a protein can be targeted specifically for antibody production. Approximately, a peptide of 10-15 residues is optimal for anti-peptide antibody production. The peptide synthesis facility is very important. The quality of an antibody is dependent upon the quality of the peptide. Side products contained in peptide products can lead to low-quality antibodies.
